NasdaqGS:ORICBiotechs
Can ORIC (ORIC) Turn Rinzimetostat’s Resistance Profile Into a Durable Prostate Cancer Moat?
ORIC Pharmaceuticals recently presented multiple posters at the 2026 AACR Annual Meeting on rinzimetostat (ORIC-944), an allosteric PRC2 inhibitor, highlighting preclinical antitumor activity in combination with darolutamide across castration-sensitive and castration-resistant prostate cancer models.
The data also suggest rinzimetostat may retain activity in settings resistant to other PRC2 inhibitors, with pharmacologic properties that could support oral use and improved tolerability.
We’ll...